Comparative efficacy of agomelatine and escitalopram in people with epilepsy and comorbid major depressive disorder: A double-blind randomized controlled trial.

In the within-group analyses ( Table 3 ), sleep quality improved slightly in both groups, but did not reach statistical significance, with PSQI scores changing from 8.00 [IQR 7.0–11.0] to 7.5 [IQR 4.5–10.0] in the agomelatine group; and from 9.00 [IQR 6.5–11.0] to 7.50 [IQR 5.0–13.0] in the escitalopram group.

also in 111,027 other papers

Within-group changes also failed to reach significance, with ESS scores remaining essentially unchanged in the agomelatine group, from 4.0 [IQR 3.0–8.0] at baseline to 5.0 [IQR 3.0–7.5] at follow-up, and showing a non-significant decrease in the escitalopram group, from 7.0 [IQR 2.0–8.0] to 5.0 [IQR 3.0–7.0].

also in 4,113 other papers